New hope for rare blood disease: drug trial shows promise in controlling PNH
NCT ID NCT06578949
First seen Nov 18, 2025 · Last updated May 13, 2026 · Updated 18 times
Summary
This study tested a drug called ravulizumab in 18 adults in China with a rare blood disease called PNH, which destroys red blood cells. The goal was to see if the drug could lower a key blood marker of cell damage and reduce the need for blood transfusions. Participants received the drug intravenously and were monitored for 26 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, CN-100730, China
-
Research Site
Guangzhou, 510100, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Nantong, 226001, China
-
Research Site
Shanghai, 200040, China
-
Research Site
Tianjin, 300020, China
-
Research Site
Tianjin, 300050, China
-
Research Site
Wuhan, 430022, China
Conditions
Explore the condition pages connected to this study.